Rennova Health, Inc. Announces Pricing of $8,600,000 Public Offering

WEST PALM BEACH, Fla.–(BUSINESS WIRE)–Rennova Health, Inc. (NASDAQ: RNVA, RNVAZ) today announced the pricing
of an underwritten public offering with expected total gross proceeds of
approximately $8,600,000 before deducting underwriting discounts and
commissions and other offering expenses payable by the Company. The
securities offered by the Company consist of Class A Units, with each
Class A Unit consisting of one share of the Company’s common stock and
one immediately exercisable five-year warrant to purchase one share of
common stock with a warrant exercise price of $0.45. The Class A Units
were priced at $0.45. The underwriters have been granted a 45-day option
to purchase up to an aggregate of an additional 15% of the securities
sold in the offering to cover over-allotments, if any. The offering is
expected to close on or about July 19, 2016, subject to customary
closing conditions. Rennova Health’s common stock is listed on the
NASDAQ Capital Market under the symbol “RNVA” and the warrants are
approved for trading on the NASDAQ Capital Market under the symbol

Joseph Gunnar & Co., LLC is acting as the sole book-running manager for
the offering.

A registration statement relating to these securities has been filed
with the Securities and Exchange Commission (the “SEC”) and was declared
effective on July 13, 2016. This offering is being made only by means of
a preliminary prospectus previously filed with the SEC which is
available on the SEC’s website located at
A final prospectus describing the terms of the offering will be filed
with the SEC and will be available on the SEC’s website located at

This press release does not constitute an offer to sell or a
solicitation of an offer to buy nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction. Any offer, if at all, will be made only by means of a
preliminary prospectus and final prospectus forming a part of the
effective registration statement. Copies of the preliminary prospectus
and final prospectus relating to this offering may be obtained, when
available, from Joseph Gunnar & Co., LLC., Prospectus Department, Thirty
Broad Street, 11th Floor, New York, New York, 10004,
telephone: 212-440-9600 or email:

About Rennova Health

Rennova Health, Inc. owns and operates five diagnostics laboratories
across the United States that provide clinical testing services
specializing in toxicology testing for pain management clinics, drug and
alcohol rehabilitation facilities and neurotransmitter testing. It
offers its customers a complete, turnkey software product including: a
proprietary laboratory ordering and reporting application, an advanced
laboratory information management system, electronic health records, and
an industry-leading platform for interpreting and reporting complex test
results to physicians. Rennova’s software is differentiated from that of
its competitors by the breadth of its services, each of which is branded
separately and is made available to physician groups in whole or in
part. The software permits efficient and easy ordering and reporting,
electronic health records integration, medical billing services and
compliance, and diagnostic interpretation. For more information see

Rennova Health Safe Harbor Statement

This press release includes forward-looking statements about Rennova
Health’s anticipated results that involve risks and uncertainties,
including statements regarding our expectations with respect to the
completion of our proposed public offering and the gross proceeds from
the offering. These statements are subject to significant risks and
uncertainties, actual results could differ materially from those
projected and Rennova Health cautions investors not to place undue
reliance on the forward-looking statements contained in this release.
There can be no assurance that Rennova Health will be able to complete
the offering on the anticipated terms, or at all. Risks and
uncertainties relating to Rennova Health and this offering can be found
in the “Risk Factors” section of the preliminary prospectus and final
prospectus related to such proposed offering to be filed with the SEC.
Rennova Health undertakes no obligation to update or revise any such
forward-looking statements to reflect subsequent events or
circumstances, except as may be required by law.


Rennova Health
Sebastien Sainsbury, 561-666-9818
Golodetz, 212-838-3777
Voss, 310-691-7100